Patricia Hurter
CMC and Preclinical Development
Laboratory research
 Vertex Pharmaceuticals Incorporated
Spain
Biography
Dr. Hurter joined Vertex in 2004 as Head of Formulation Development, became the Vice President of Pharmaceutical Development in 2006, and is currently the Senior Vice President of CMC and Preclinical Development. The scope of her responsibilities include Pharmaceutical Development (development of chemical processes for drug substance manufacture as well as drug product formulation and process development, and associated characterization methods for activities from the discovery phase through to validation for commercial manufacturing), DMPK (preclinical drug metabolism and pharmacokinetics) and drug safety evaluation. Prior to joining Vertex, Dr. Hurter was Director of Formulation Development at Merck from 2000 to 2004. Before joining the pharmaceutical industry, Dr. Hurter worked in the paper industry for 8 years where she studied the microstructure of paper and its effects on end use performance. Dr. Hurter has a Ph.D. in Chemical Engineering from MIT, an M.S. in Mechanical Engineering from West Virginia University and a B.Sc. in Chemical Engineering from the University of Natal, Durban, South Africa.
Research Interest
Her area of research interest includes Pharmaceutical Development (development of chemical processes for drug substance manufacture as well as drug product formulation and process development, and associated characterization methods for activities from the discovery phase through to validation for commercial manufacturing), DMPK (preclinical drug metabolism and pharmacokinetics) and drug safety evaluation
